Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

N-Hydroxypiridinedione: A Privileged Heterocycle for Targeting the HBV RNase H

Molecules(2024)10.3390/molecules29122942Source: DataRank Database

N-Hydroxypiridinedione: A Privileged Heterocycle for Targeting the HBV RNase H is a research paper published in Molecules (2024). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)OA: goldTopics (43)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Maria Makri,Georgia‐Myrto Prifti,Aristeidis Chiotellis ORCID,Alexandros Pappas,Molly E. Woodson

Live enrichment

PubMed:38931006

NIH

Grant: R01 AI150610

NIH

Grant: R21 AI124672

NIH HHS

Grant: S10 OD032206

National Institutes of Health

Grant: ‘ASKLEPIOS Grants Program’

Gilead

Grant: 'ASKLEPIOS Grants Program'

National Institutes of Health

Grant: 1R01AI150610-01A1

Lead optimization of Hepatitis B Virus ribonuclease H inhibitors

National Institutes of Health

Grant: 1R21AI124672-01A1

Defining approaches for improving HID and HPD compounds as HBV RNaseH antagonists

goldLicense: CC BY

publisherhttps://www.mdpi.com/1420-3049/29/12/2942/pdf

https://doi.org/10.3390/molecules29122942

https://pubmed.ncbi.nlm.nih.gov/38931006

http://dx.doi.org/10.3390/molecules29122942

https://doaj.org/article/92d2fc12da214c62bb8eb197a88cae60

Fields of Study

Hepatitis B virusVirus ReplicationAntiviral AgentsRibonuclease HHumansStructure-Activity RelationshipMolecular Docking SimulationCatalytic DomainOximesMolecular StructureHep G2 CellsEnzyme Inhibitors

MeSH Terms

HumansHepatitis B virusOximesEnzyme InhibitorsAntiviral AgentsVirus ReplicationMolecular StructureCatalytic DomainStructure-Activity RelationshipRibonuclease HHep G2 CellsMolecular Docking Simulation

Keywords

Hepatitis B virusOximesStructure–activity RelationshipsRibonuclease HAnti-hbv AgentsN-hydroxypyridinedionesMolecular Structure<i>N</i>-hydroxypyridinedionesOrganic chemistryHep G2 CellsVirus ReplicationAntiviral AgentsArticleMolecular Docking SimulationStructure-Activity RelationshipQD241-441Catalytic DomainHumansEnzyme Inhibitors

Sustainable Development Goals

SDG 3: 3. Good health